Syngenta’s record
The fourth firm in the cartel — now Chinese state-owned — has one settlement that is history and one lawsuit that is still being fought. We grade them differently, and say why.
Syngenta rushed a genetically engineered corn trait to the U.S. market before China would accept it, China slammed the door on American corn, and the company ended up paying roughly $1.5 billion to hundreds of thousands of farmers — one of the largest agricultural-litigation settlements on record. Separately, thousands of people with Parkinson’s disease are suing Syngenta over its weedkiller paraquat, alleging the company long knew of a risk. The first is settled fact; the second is an unproven allegation, and we keep the two apart.
What this page is about
Syngenta — the Basel-based seed-and-chemical giant acquired in 2017 by the Chinese state-owned ChemChina — is the fourth firm in this cartel, and it carries two very different marks. First, the Viptera debacle: Syngenta sold its genetically engineered MIR162 corn trait (branded Agrisure Viptera, and later Duracade) in the United States before China had approved it for import; when Chinese authorities rejected U.S. corn shipments, prices fell and farmers sued. In In re Syngenta AG MIR 162 Corn Litigation (MDL No. 2591, D. Kan.), Syngenta agreed to a class settlement of roughly $1.51 billion, granted final approval in December 2018 — among the largest agricultural-litigation settlements in U.S. history.
Second, and unresolved: paraquat. Thousands of people with Parkinson’s disease have sued Syngenta in a federal multidistrict litigation (In re Paraquat Products Liability Litigation, MDL No. 3004, S.D. Ill.), alleging the company long knew its weedkiller was linked to the disease and failed to warn. Those are allegations that have not been proven in court. We grade the Viptera settlement as fact and the paraquat claims as an active, unadjudicated dispute.
Books that go deeper on this story. Links are Amazon affiliate searches — buying through them supports the work at no cost to you.
The same investigation, restaged one beat at a time. Step through it here, or present it fullscreen.
Syngenta's record.
The fourth firm in the cartel — now Chinese state-owned — has one settlement that is history and one lawsuit still being fought. We grade them differently.
The record, in order
Every dated event on this page, assembled chronologically. The page may cover events in a different order for the narrative; this is the straight timeline.
Two entries, graded differently
Viptera: the GM corn sold ahead of China's approval, and the ~$1.51B settlement
FACTSyngenta commercialized its genetically engineered MIR162 corn trait — sold as Agrisure Viptera, and later Duracade — in the United States before China, a major buyer, had approved it for import. Beginning in 2013, Chinese authorities rejected U.S. corn shipments found to contain the unapproved trait, and corn prices fell; U.S. farmers, exporters and others sued, arguing Syngenta had launched the trait prematurely. The claims were consolidated in In re Syngenta AG MIR 162 Corn Litigation, MDL No. 2591, in the U.S. District Court for the District of Kansas. Syngenta agreed to a class settlement of approximately $1.51 billion, to which the court granted final approval in December 2018, covering hundreds of thousands of corn producers — one of the largest agricultural-litigation settlements in U.S. history. The settlement resolved the claims without any admission of liability.
- In re Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 (U.S. District Court, District of Kansas) — ~$1.51 billion class settlement, final approval December 2018
- Reuters — reporting on the Syngenta ~$1.5 billion GMO-corn settlement with U.S. farmers over the MIR162/Viptera trait sold ahead of Chinese import approval
Paraquat and Parkinson's: an active lawsuit, not an adjudicated fact
SOME SMOKESyngenta manufactures the weedkiller paraquat (Gramoxone). Thousands of people with Parkinson's disease, or their families, have sued Syngenta (and co-defendant Chevron, a former distributor) in a consolidated federal proceeding — In re Paraquat Products Liability Litigation, MDL No. 3004, before the U.S. District Court for the Southern District of Illinois — alleging that exposure to paraquat causes or contributes to Parkinson's and that the company long knew of the risk but failed to adequately warn. Plaintiffs point to internal documents surfaced in the litigation. Syngenta denies that paraquat causes Parkinson's and contests the claims. These are allegations that have not been proven; the regulatory picture is also mixed, with the U.S. EPA having permitted continued use under restrictions. We grade the existence of the litigation as fact and the underlying causation/knowledge claims as an unresolved dispute, attributed to the plaintiffs and the court record — not asserted as our finding.
The fourth firm, and the discipline of grading
Syngenta completes the quartet — Bayer, Corteva, Syngenta, BASF — that the consolidation left standing, and its two marks show why this hub insists on grading each claim rather than lumping them together. The Viptera settlement is over, the number is fixed, and it is fact. The paraquat suits are live, the science and the liability are contested, and honesty requires calling them allegations even where the internal documents look damning. That discipline is the whole difference between an investigation and a pile-on. It is also the bridge to the pesticide immunity playbook: the same industry that captures the referee and ghostwrites the science works to make sure the paraquat plaintiffs face the same uphill fight that Roundup plaintiffs did — which is exactly why an ongoing case, graded honestly, still belongs on the ledger.
If you are named on this page
If you are named on this page, or are a party materially affected by the claims made here, and you wish to respond, correct the record, or add context, use the Contact page. Responses are published verbatim alongside the original claim, with the sender identified and the date of receipt. The channel stays open for the life of the page.
This site aggregates and grades a record that other outlets and primary sources have already put on the record. Every FACT-graded claim above is sourced to court filings, government reports, sworn whistleblower disclosures, published investigative journalism, or named-source statements. The citations are the accountability mechanism; this section is how you get on the record too.